TORONTO, ON / ACCESSWIRE / August 12, 2022 / StageZero Life Sciences (“StageZero” or the “Firm”) (TSX:SZLS) immediately introduced that it’ll launch its second quarter operational and monetary outcomes earlier than the markets open on Tuesday, August 16, 2022. StageZero’s Chairman and CEO, James Howard-Tripp, will host a convention name and accompanying webcast at 8:30 a.m. EDT on Tuesday August 16, 2022, to evaluate the operational outcomes and talk about enterprise developments to this point.
Analyst and Investor Name
Occasion Date: Tuesday August 16, 2022
Time: 8:30 a.m. EST
Webcast Hyperlink: https://www.webcaster4.com/Webcast/Web page/2082/46389
Participant Numbers:
Toll Free: 888-506-0062
Worldwide: 973-528-0011
Participant Entry Code: 811487
Replay Quantity:
Toll Free: 877-481-4010
Worldwide: 919-882-2331
Replay Passcode: 46389
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically built-in healthcare firm devoted to enhancing the early detection and administration of most cancers and different persistent ailments by way of next-generation diagnostics and distinctive telehealth packages that present medical interventions to help sufferers who at present have most cancers (COC Protocol) in addition to assist sufferers scale back the danger of creating late-stage illness (AVRT™).
The Firm’s subsequent technology check, Aristotle®, is the primary ever mRNA multi-cancer panel for concurrently screening for a number of cancers from a single pattern of blood with excessive sensitivity and specificity for every most cancers. Aristotle® makes use of mRNA expertise to establish the molecular signatures of a number of most cancers sorts and is constructed on the Firm’s patented expertise platform, the Sentinel Precept. This underlying expertise has been validated in additional than 9,000 sufferers and utilized by greater than 100,000 sufferers in North America.
The Care Oncology Clinic affords a supervised remedy routine (the COC Protocol) for folks identified with most cancers of any sort or stage. Developed by scientists and oncologists, the COC Protocol is meant for adjunctive administration alongside standard-of-care most cancers remedy. It’s an individualized therapeutic method which seeks to concurrently goal a number of metabolic most cancers pathways. The goal is to limit most cancers cell vitality provide and use, which can make it harder total for most cancers cells to outlive, develop and adapt to altering circumstances within the physique. Consequently, such cells can probably turn out to be extra susceptible to assault from cell-killing therapies similar to radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted method, supported by peer-reviewed scientific research, which spotlight the potential of sure therapies to focus on the precise vitality necessities of most cancers cells, impacting their potential to develop and multiply.
AVRT is a Doctor-Led, telehealth program for figuring out and managing the early warning indicators of most cancers and persistent illness. Our program contains: a complete on-line well being analysis; blood assessments to measure markers of irritation and metabolism; an in-depth preliminary doctor session; common doctor follow-up appointments and interval screening.
Aristotle®, in addition to further most cancers diagnostics (ColonSentry®, BreastSentry™, and the Prostate Well being Index) are processed on the Firm’s medical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA licensed high-complexity reference laboratory in Richmond, Virginia. As well as, the Firm can also be leveraging its specialty in polymerase chain response (PCR) testing to offer COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood evaluation).
StageZero Life Sciences trades on the Toronto Inventory trade underneath the image SZLS and on the OTCQB underneath the image SZLSF.
Ahead-Trying Statements
This press launch incorporates forward-looking statements recognized by phrases similar to “expects”, “will” and related expressions, which replicate the Firm’s present expectations relating to future occasions. The forward-looking statements contain dangers and uncertainties that would trigger the Firm’s precise occasions to vary materially from these projected herein. Traders ought to seek the advice of the Firm’s ongoing quarterly filings and annual reviews for extra info on dangers and uncertainties relating to those forward-looking statements. The reader is cautioned to not depend on these forward-looking statements. The Firm disclaims any obligation to replace these forward-looking statements, besides as required by legislation.
For additional info please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View supply model on accesswire.com:
https://www.accesswire.com/711905/StageZero-to-Maintain-Q2-2022-Operational-and-Monetary-Outcomes-Convention-Name-on-Tuesday-August-16-2022
